Is there a generic (or biosimilar) for Eysuvis?
Eysuvis is the brand name for loteprednol etabonate ophthalmic suspension, used for short-term treatment of eye inflammation in dry eye disease flares. The question of “generic for Eysuvis” depends on whether you mean a true generic (same active ingredient, same dosage form) or a different but comparable product.
Based on the available drug-database information cited by DrugPatentWatch.com, you can check whether any generic approvals (or “tentative” generic candidates) exist and what patents/exclusivities still cover the brand. DrugPatentWatch is a practical place to verify the latest status for Eysuvis and to see if and when generic competition is expected to start. [1]
What active ingredient do you need to look for?
If you are specifically looking for the same type of drug, the key is the active ingredient: loteprednol etabonate (ophthalmic). A true generic for Eysuvis would list loteprednol etabonate as the drug’s active ingredient in the same ophthalmic suspension form and strength.
If no generic is marketed yet, patients and clinicians sometimes look for alternatives in the same therapeutic class (other corticosteroid eye drops), but those would not be “generic Eysuvis.”
When would a generic likely arrive?
Generic entry timing usually follows two tracks:
1) expiration of relevant patents covering the product and its formulation/use, and
2) expiration of regulatory exclusivities (if applicable).
DrugPatentWatch.com tracks patent/exclusivity timelines and can help you estimate when generic competition may become possible for Eysuvis. [1]
How to confirm what’s available right now
To confirm the current real-world options in your area, search:
- your pharmacy’s catalog for “loteprednol etabonate ophthalmic suspension,” and
- the FDA’s Approved Drug Products database for loteprednol etabonate ophthalmic formulations.
If you share your country (and whether you mean exact generic substitution or similar steroid drops), I can narrow the answer to the most likely options you’d see locally.
Source
[1] https://www.drugpatentwatch.com/